Overview

A class action lawsuit has been filed against Merck & Co., Inc. (“Merck” or the “Company”) and certain of the Company’s former senior executive officers alleging violations of the federal securities laws.  The Company’s common stock traded on the New York Stock Exchange (the “NYSE”) under the symbol “MRK.”

The Merck class action lawsuit was brought on behalf of all persons and entities who purchased or otherwise acquired Merck securities between February 3, 2022, to February 3, 2025, both dates inclusive (the “Class Period”).

The Merck class action lawsuit alleges that Defendants provided investors with material information concerning Merck’s expected revenue of $11 billion from sales of Gardasil by 2030.  Defendants’ statements included, among other things, confidence in Merck’s purported ability to utilize successful consumer activation and education efforts on the benefits of Gardasil in order to drive demand and capitalize on eligible populations for vaccination, resulting in confidently optimistic reports and forecasts of Gardasil’s growth in China.

Defendants provided these overwhelmingly positive statements to investors while, at the same time, disseminating materially false and misleading statements and/or concealing material adverse facts concerning the true state of Gardasil’s demand in China; notably, that Merck lacked visibility into demand for Gardasil in China among eligible and otherwise targeted populations, resulting in the inflated inventory of its distributor, Zhifei.  Such statements absent these material facts caused Plaintiff and other shareholders to purchase Merck’s securities at artificially inflated prices.

*          *          *

If you purchased or otherwise acquired Merck securities between February 3, 2022, to February 3, 2025, both dates inclusive, and you wish to serve as lead plaintiff in this lawsuit, we encourage you to submit your information to DiCello Levitt LLP via the form on this page. 

You can also contact DiCello Levitt partner Brian O’Mara by calling (888) 287-9005 or at [email protected]. 

The deadline to apply to the Court to serve as lead plaintiff in the Merck class action lawsuit is April 14, 2025.